Press Releases

Date Title and Summary  
Toggle Summary Aimmune Therapeutics to Participate in Three Investor Conferences in September
BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 6, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will be presenting at three upcoming investor
Toggle Summary Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 9, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview at the 2017 Wedbush PacGrow Healthcare
Toggle Summary Aimmune Therapeutics Announces Second Quarter 2017 Financial Results
BRISBANE, California --(BUSINESS WIRE)--Aug. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2017 .
Toggle Summary Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy
— Discovery of T H 2A Cells by Benaroya Research Institute Scientists, Led by Erik Wambre, Ph.D., Could Focus Future Allergy Research — — AR101 Treatment Linked to Decrease in T H 2A Cells in Samples from Peanut-Allergic Patients from ARC001 Trial — BRISBANE, Calif. --(BUSINESS WIRE)--Aug.
Toggle Summary Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
— Trial Will Augment Ongoing Phase 3 PALISADE Trial and Explore Endpoint of Tolerating at Least 1000-mg Dose of Peanut Protein to Support AR101 Regulatory Filings in Europe — BRISBANE, Calif. --(BUSINESS WIRE)--Jul. 5, 2017-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress
BRISBANE, Calif. & HELSINKI--(BUSINESS WIRE)--Jun. 20, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today reported findings from pre-randomization, preliminary clinical data collected from the European
Toggle Summary Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017
— Abstracts Report on Screening Population for PALISADE Phase 3 Clinical Trial and Current Management of Peanut Allergy — BRISBANE, California --(BUSINESS WIRE)--Jun. 15, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food
Toggle Summary Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
— Final Study Visits Projected Around Year-End 2017; Topline Data Expected in the First Quarter of 2018 — — More Than 97 Percent of Patients Currently On Study Are Through the Up-Dosing Phase — BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 12, 2017-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th
BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview at the Goldman Sachs 38 th Annual Global
Toggle Summary Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy
— Florida Plant Can Produce AR101 for Peanut Allergy for Global Market — BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 7, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today hosted a ribbon-cutting ceremony to
Toggle Summary Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
— “Real-World” Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif. --(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007)
Toggle Summary Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
BRISBANE, Calif. --(BUSINESS WIRE)--May 9, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly , M.B.B.S.,
Toggle Summary Aimmune Therapeutics Announces First Quarter 2017 Financial Results
BRISBANE, Calif. --(BUSINESS WIRE)--May 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced financial results for first quarter
Toggle Summary Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
— New CFO Is an Established Leader and Healthcare Industry Veteran — BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 13, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the appointment of Eric Bjerkholt as Chief Financial Officer. Mr. Bjerkholt joins Aimmune from Sunesis Pharmaceuticals,
Toggle Summary Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
— Company Began 2017 with Approximately $283 Million in Cash and Investments, Sufficient to Support Current Development Plans through Regulatory Submissions — — Conference Call and Webcast Today at 8:00 a.m. ET — BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 15, 2017-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017
- Conference Call and Webcast to Follow at 8:00 a.m. ET / 5:00 a.m. PT - BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its financial results for
Toggle Summary Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
— Unique Dataset of Double-Blind, Placebo-Controlled Food Challenges from Phase 3 PALISADE North American Screened Population Is Largest Ever Collected on Peanut-Allergic Patients and Provides Valuable Insights for Future Study — — 95% Adherence to Daily At-Home AR101 Dosing in Blinded Phase 2
Toggle Summary Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 1, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly , M.B.B.S.,
Toggle Summary Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 27, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that new clinical data on AR101 will
Toggle Summary Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
— AR101 Program to Initially Address Urgent Unmet Need of Peanut-Allergic Patients Ages 4-17, Consistent with Breakthrough Therapy Designation — — Potential BLA Filing to Include Safety Database of 600 Patients, Achievable with Current Phase 3 Program — — Conference Call Today at 5:00 p.m.
Toggle Summary Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
Presentation on Wednesday, January 11, 2017 , at 5:00 p.m. Pacific Time BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 4, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for
Toggle Summary Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts
— Five Leading Food Allergy Researchers and Clinicians Form Distinguished Board — BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 1, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for
Toggle Summary Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
— Top-Line PALISADE Data Expected in 4Q 2017 — — New Clinical Study: ARTEMIS Dedicated European Pediatric Trial of AR101 Will Explore Protection at an Endpoint of Tolerating 2,043 mg of Peanut Protein after Nine Months of Treatment — BRISBANE, Calif. --(BUSINESS WIRE)--Nov.
Toggle Summary Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 28, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced the closing of the $145 million
Toggle Summary Aimmune Therapeutics to Host Investor Symposium Featuring Leading Experts in Peanut Allergy
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 21, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that it will host an Investor
Toggle Summary Aimmune Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 14, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced financial results for the third
Toggle Summary Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics
— Nestlé Health Science to Make Investment through the Purchase of Nearly 7.6 Million Shares of Aimmune Stock at $19.20 per Share — — Companies Enter into Strategic Collaboration Agreement Designed to Enable the Successful Development and Commercialization of Innovative Food Allergy Therapies — —
Toggle Summary Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences
BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 31, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that Stephen G.
Toggle Summary Aimmune Therapeutics to Participate in Two Upcoming Medical Meetings
BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 11, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that it will present Phase 2 clinical
Toggle Summary Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S.
— PALISADE Top-Line Results Expected in 4Q 2017 — — New RAMSES Real-World Experience Study, to Begin in 1Q 2017, Will Evaluate AR101 and Use of Potential Predictive Peanut-Specific Biomarkers Without Requiring an Oral Food Challenge for Study Entry — — Management to Host Conference Call at 5:00
Toggle Summary Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children
─ Academic Study Recently Published in the Journal of Allergy and Clinical Immunology Provides Support for Aimmune’s Planned Pediatric Trial of AR101 ─ ─ Conference Call on Monday, August 22, 2016 , at 4:30 p.m. Eastern Time ─ BRISBANE, Calif. --(BUSINESS WIRE)--Aug.
Toggle Summary Aimmune Therapeutics Announces Second Quarter 2016 Financial Results
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 10, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced financial results for the second
Toggle Summary Aimmune Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 9, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that Stephen G.
Toggle Summary Aimmune Therapeutics Appoints Daniel Adelman, M.D., as Chief Medical Officer
— New CMO Is a Seasoned Clinical Development Leader and Food Allergy and Immunology Expert — BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 21, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy)
Toggle Summary Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy
— Dr. Rima A. Rachid of Harvard Medical School and Boston Children’s Hospital Presented Data in a Late-Breaking Oral Abstract Session at EAACI Congress 2016 — — Patients on CODIT™ (Low-Dose) AR101 Extended Maintenance Therapy Experienced Minimal and Primarily Mild Adverse Events, and None
Toggle Summary Aimmune Therapeutics Announces Late-Breaker Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016
— Dr. Rima Rachid Will Present Data on the Safety and Tolerability of AR101 for Peanut Allergy after More than One Year of Treatment — — Management Will Host Conference Call on Monday, June 13, 2016 , at 4 p.m. ET — BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 7, 2016-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics to Present at Upcoming June Investor Conferences
BRISBANE, Calif. --(BUSINESS WIRE)--May 31, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that Stephen G.
Toggle Summary Aimmune Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update
BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced financial results for the first
Toggle Summary Aimmune Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
BRISBANE, Calif. --(BUSINESS WIRE)--May 4, 2016-- Aimmune Therapeutics , Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized  O ral  D esensitization  I mmuno T herapy) treatments for life-threatening food allergies, today announced that Stephen G.
Toggle Summary Aimmune Therapeutics Presents Data on Biomarkers and Potential to Predict Response to Peanut Allergy Treatment With AR101
— Aimmune Discussed Phase 2 Data, Including Peanut-Specific IgE Values, at FARE Research Retreat — BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 11, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy)
Toggle Summary Aimmune Therapeutics Appoints Douglas Sheehy as General Counsel and Secretary
BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 5, 2016-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ (characterized oral desensitization immunotherapy) treatments for life-threatening food allergies, today announced the appointment of Douglas Sheehy as General
Toggle Summary Aimmune Therapeutics Announces Phase 2 Follow-On Study of AR101 for the Treatment of Peanut Allergy Demonstrated Increased Desensitization and Improved Tolerability with Low-Dose Maintenance
— All Patients Who Completed 12 Weeks of Low-Dose Maintenance Therapy in the ARC002 Trial Were Desensitized to Levels of Peanut Protein Far Exceeding Those of Typical Accidental Exposures — — Dr. J. Andrew Bird Presented Data Confirming Safety and Demonstrating Efficacy of AR101 for the Treatment
Toggle Summary Aimmune Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
─ Company Began 2016 with Approximately $200 Million in Cash and Investments and Its Phase 3 PALISADE Trial Underway for Peanut Allergic Patients ─ ─ Late-Breaker Presentation on New AR101 Phase 2 Data This Sunday at AAAAI ─ ─ Conference Call and Webcast Today at 5 p.m. Eastern Time / 2 p.m.
Toggle Summary Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
─ Cowen and Company 36 th Annual Health Care Conference ─ ─ Barclays Capital Global Healthcare Conference ─ ─ Webcasts Available Through Aimmune Corporate Website ─ BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 1, 2016-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results on Thursday, March 3, 2016
— Webcast and Conference Call to Follow — BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 25, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that its financial results for the fourth quarter and full
Toggle Summary Aimmune Therapeutics Announces Presentation at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
— Aimmune Late-Breaking Abstract Posted Online Today by The Journal of Allergy and Clinical Immunology (JACI) — — Dr. J. Andrew Bird Will Present Data on the Efficacy and Safety of AR101 for the Treatment of Peanut Allergy from the ARC002 Phase 2 Follow-On Trial — BRISBANE, Calif.
Toggle Summary Aimmune Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
— Presentation on Monday, February 8, 2016 , at 9:00 a.m. ET — BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 1, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that CEO Stephen Dilly , M.B.B.S., Ph.D.,
Toggle Summary Aimmune Therapeutics Enrolls First Patient in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
— Aimmune Provides Year-End Update and Upcoming Milestones Review — BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 11, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, announced today that it has enrolled the first
Toggle Summary Aimmune Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
— Presentation on Thursday, January 14, 2016 , at 11:00 a.m. Pacific Time — BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 6, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that CEO Stephen Dilly ,
Toggle Summary Aimmune Therapeutics Appoints Jeffrey H. Knapp as Chief Operating Officer
— Operational Leadership and Deep Commercial Experience Key as Aimmune Launches Pivotal Phase 3 PALISADE Clinical Trial — BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 17, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food
Toggle Summary Aimmune Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference
— Presentation on December 1, 2015 , at 2:00 p.m. ET — BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 16, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the Piper Jaffray 27th
Toggle Summary Aimmune Therapeutics Reports Positive Findings for ARC002 Follow-On Phase 2 Study of AR101 for Treatment of Peanut Allergy
— Aimmune Plans to Release Full ARC002 Data at AAAAI Meeting in March 2016 — BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 11, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced positive findings for its
Toggle Summary Aimmune Therapeutics Announces Financial Results for the Third Quarter 2015
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 4, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced financial results for the third quarter and nine months ended September 30, 2015 .
Toggle Summary Aimmune Therapeutics to Present at the 2015 Credit Suisse Healthcare Conference
— Presentation on November 11, 2015 , at 2:00 p.m. MT — BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 2, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the 2015 Credit Suisse
Toggle Summary Aimmune Therapeutics Announces COO Transition
— COO Howard Raff to Retire from Leadership Position to Focus on Future Pipeline Development — — Aimmune Builds Clinical Team with Key Allergist / Immunologist Hires — BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 9, 2015-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics Receives EMA Decision Agreeing With PIP for AR101 for the Treatment of Peanut Allergy
BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 7, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it has received the European Medicines Agency (EMA) decision endorsing the company’s pediatric
Toggle Summary Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
— Presentation on September 18, 2015 , at 9:45 a.m. GMT — BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 2, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the Bank of America
Toggle Summary Aimmune Therapeutics Reports Second Quarter 2015 Financial Results
-- IPO Netted $168 Million for Strong Cash Position -- -- Phase 3 Trial Planned for Early 2016 Based on Successful Phase 2 Trial -- BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 31, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for
Toggle Summary Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 11, 2015-- Aimmune Therapeutics, Inc. , today announced the closing of its initial public offering of 11,499,999 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, which includes the
Toggle Summary Aimmune Therapeutics Announces Pricing of Initial Public Offering
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 5, 2015-- Aimmune Therapeutics, Inc. today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions.
Toggle Summary Aimmune Therapeutics Files Registration Statement for Initial Public Offering
BRISBANE, Calif., July 6, 2015 — Aimmune Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price
Toggle Summary Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101
FDA Breakthrough Therapy Designation for AR101 oral immunotherapy of peanut-allergic children and adolescents follows positive Phase 2 study results BRISBANE, Calif., June 18, 2015 — Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for
Toggle Summary Aimmune Therapeutics Announces Positive Phase 2 Study Results of AR101 for the Treatment of Peanut Allergy
Positive topline results demonstrate AR101 appears to be a well-tolerated and effective treatment option for peanut allergy in a controlled desensitization regimen, as all study completers in active group met the primary desensitization endpoint Data presented in a late-breaking oral abstract
Toggle Summary Aimmune Therapeutics to Announce Phase 2 Data at EAACI Congress 2015 for Study of Peanut Allergy Desensitization Treatment
Dr. Wesley Burks of the University of North Carolina will present study data BRISBANE, Calif., June 3, 2015 — Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that the topline results from its Phase 2
Toggle Summary Allergen Research Corporation Renamed Aimmune Therapeutics
BRISBANE, Calif., May 27, 2015 — Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced that the company has changed its name from Allergen Research Corporation (ARC) to Aimmune Therapeutics.
Toggle Summary Allergen Research Corporation Names Mark McDade as Chairman and Mark Iwicki as Member of the Board of Directors
BRISBANE, Calif., May 18, 2015 – Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced additions to the company’s Board of Directors: Mark McDade, joining as Chairman; and Mark Iwicki, joining
Toggle Summary Allergen Research Corporation Announces New CFO Warren DeSouza and Board of Directors Audit Committee Chair Kate Falberg
SAN MATEO, Calif., April 21, 2015 — Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced leadership appointments for the company’s key financial functions.
Toggle Summary Allergen Research Corporation Expands Management with New VP Functions
Mary Rozenman, PhD, Joins ARC as Senior Vice President, Corporate and Commercial Development, and Mike Holfinger, PhD, Joins as Vice President, Manufacturing SAN MATEO, Calif., April 8, 2015 – Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing
Toggle Summary Allergen Research Corporation Completes $80 Million Series B Financing to Advance Drug Development Portfolio for Food Allergy
Jim Tananbaum, MD, and Stacey Seltzer Join ARC Board of Directors SAN MATEO, Calif., March 12, 2015 – Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced the completion of an $80 million
Toggle Summary Allergen Research Corporation Initiates Phase 2b Clinical Trial for Peanut Allergy Oral Immunotherapy (OIT)
Study Marks Progress toward Making Gains from OIT Research Clinically Available for Food Allergy Treatment SAN MATEO, Calif., February 27, 2014— Allergen Research Corporation (ARC), a privately held company developing desensitization treatment protocols and products for food allergies, today
Toggle Summary Allergen Research Corporation Announces $17 Million Series A Financing
Funds Will Support Phase 2b Clinical Trial for Peanut Allergy Oral Immunotherapy SAN MATEO, Calif., November 21, 2013— Allergen Research Corporation (ARC), a privately held company developing desensitization treatment protocols and products for food allergies, today announced the successful